Literature Review Demographics of The End-Stage Renal Disease Population
Literature Review Demographics of The End-Stage Renal Disease Population
Literature Review Demographics of The End-Stage Renal Disease Population
Literature review
Anemia in ESRF
Anemia meant there was a low supply of red blood cells (RBC) in
the body. Red blood cells carried oxygen from your lungs to all
your organs and tissues. They provided energy for our daily
activities. Anemia was a major complication of stages 2-5 CKD
affecting more than 50% ESRD patients before treatment. Anemia
especially hemoglobin (Hb) below 11 g/dL could have a
devastating impact secondary to chronic renal failure had been
associated with cardiovascular complications including left
ventricular hypertrophy and congestive heart failure (CHF),
reduced cognitive function, decreased quality of life and, more
importantly, mortality (Tang, Fung, Chu, Lee, Cheuk, Yim, Chan,
Tong, 2007; Silverberg, Wexler, Blum, Schwartz and Iaina, 2004).
Furthermore, correction of anemia would eliminate the need of
regular blood transfusion, which increased the risk of transfusion-
related viral transmission and sensitization for subsequent
transplantation (Lai, 2009; Nissenson and Fine, 2008). Therefore,
early treatment of anemia would stop the progression of CKD and
CHF. It was because their kidneys failed to make enough of a
certain hormone, which called erythropoietin (EPO). EPO helped
bone marrow make RBC. There was anemia if Hb level was lower
than the normal range (which was 12.0 for women and 13.5 for
men). Erythropoiesis-stimulating agents (ESAs) act like the natural
hormone EPO, which helped our body to make red blood cells.
Short-acting ESAs are more effective when given subcutaneously
(as an injection under the skin) rather than by intravenous
(through the blood tubes during dialysis). Examples of short-
acting ESAs were epoetin alfa and epoetin beta. Long-lasting ESAs
were equally effective regardless of how they were given.
Darbepoetin was an example of a long lasting ESA (National
Kidney Foundation (NKF), 2006). Recombinant human
erythropoietin (rHuEPO) including Eprex and Recormon had been
widely used for treatment of renal anemia. However, up to 25% of
dialysis patients were relatively resistant to replacement requiring
higher doses to reach target Hb concentration (11 g/dL), and 5-
10% fail to respond even on high doses of ESAs (Lam, 2009). The
National Kidney Foundation’s 2007 Update of the Kidney Disease
Outcomes Quality Initiative (KDOQI) Clinical Practice Guidelines
and Recommendations for Hemoglobin Target advised that the
hemoglobin target should generally be in the range of 11 -12
g/dL. The Hb target should not be greater than 13.0 g/dL was
based on analysis of all-cause mortality and adverse
cardiovascular events in patients with CKD assigned to Hb
targeted greater than 13.0 g/dL compared with lower Hb targeted
for ESA therapy (NKF, 2007).
Nursing assessment
Past medical history
Autosomal dominant polycystic kidney disease (ADPKD)
Allergies
Review of system
Nutrition: he did not like to take the diet and snack provided by
the hospital. He did not cook the meal by himself; he usually had
the meal in the fast food shop when he felt hungry but not at
regular time. He denied any food allergy or intolerance and intake
of caffeine (coffee, tea, soft drinks). He said he did not have any
food restriction as he ate whatever he liked (Jarvis C, 2007 and
Phillips, 2009).
Conclusion
Chronic renal failure required long-term and multidiscipline to
tailor each client’s need concerning their physical, psychosocial
and environmental need. No matter which type of dialysis they
used, they were waiting for renal transplantation hopelessly due
to shortage of organ. Self-care at home was encouraged in Hong
Kong. However, in the unit policy of Tuen Mun Hospital, there was
no case manager to collaborate process of on-going assessment,
planning, facilitation and advocacy for options and services to
meet an individual’s health needs through communication and
available resources to provide continuity of care and thus lower
hospitalization. Also, lack of follow up to detect problems was
another policy problem. Health care professionals could detect
the physical and psychosocial problems and referred other
discipline promptly when necessary in follow up. Case
management seemed to be a new strategies dealing with chronic
disease.
References
Ching C.S.Y., Pun O.M., Wong K.S., Chan C.L.K. (2000). Quality of
life of continuous ambulatory peritoneal dialysis (CAPD) patients.
Hong Kong Journal of Nephrology, 2(2), 98-103.
http://www.ifcc.org/PDF/20010903.pdf
http://www.cc.nih.gov/ccc/patient_education/pepubs/copechron.p
df
http://www.kidney.org/PROFESSIONALS/kdoqi/guidelines_bone/g
uide13a.htm
http://www.kidney.org/atoz/pdf/AnemiaStage5.pdf
http://www.kidney.org/atoz/pdf/anemia.pdf
http://www.kidney.org/professionals/kdoqi/guidelines_anemia/cpr
21.htm
http://www.kidney.org/atoz/content/polycystic.cfm
Silverberg D., Wexler D., Blum M., Schwartz D. and Iaina A. (2004).
The association between congestive heart failure and chronic
renal failure disease. Current Opinion in Nephrology and
Hypertension, 13, 163-170.
Tang H.L., Fung K.S., Chu K.H., Lee W., Cheuk A., Yim K.F., Chan
H.W.H., Tong K.L. (2007). Conversion from recombinant human
erythropoietin to once every 4 weeks darbepoetin alfa for
treatment of renal anemia in CAPD patients. Hong Kong Journal
of Nephrology, 9(2), 77-81.
Appendix 1
Current medication
CAPD Baxter ultra bag (low calcium)
Oral: 5 mg daily
Oral: 20 mg bd
Tropical: bd